2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes, engl.

Year of publication: 2023

Editing medical society(ies):
European Society of Cardiology (ESC)

Other medical societies involved: 51

ESC Guidelines


List of evaluated guidelines

Evaluation by Leitlinienwatch

03.09.25


PTs.

Criterion
2

Transparency

The names in the list of authors of the guideline are not identical to the names in the "ESC Declaration of Interest Report", in some cases first and last names have been swapped. The "ESC Declaration of Interest Report" does not explain the difference between "TF members", "Reviewers" and "Clinical Practice Guidelines Committee 2022-2024". The exact affiliations of the "reviewers" are not specified. Conflicts of interest are not specified for each author, e.g. conflicts of interest and exact affiliation of the representative of the patients and conflicts of interest of the "Document Group" are not specified. Despite these ambiguities, we award 2 points.
0

Composition of the Guideline Working Group

The "guideline group" cannot be clearly defined. In the title and introduction, a distinction is made between "TF members", "Reviewers", "Document Group", "Patient Forum" and "Clinical Practice Guidelines Committee". A total of 145 people are named in the report. Of these, 116 (= 80%) report conflicts of interest in the period 2020-2022.
0

Independence of the Coordinators/Chairs/Lead AuthorsUnabhängigkeit der Vorsitzenden/federführenden Autoren

Four lead authors are named. All of them declare conflicts of interest.
0

Abstention from Voting

The procedure for voting is not explained in detail.
0

External Review of the Guideline

External advice is not explained in detail.
1

Bonus Points

A comprehensive "internal review" was carried out.

Explanations to the evaluation criteria

Overall score

3

Good! (11-18)

Warning! (6-10)

Needs reform! (0-5)

Comment

Unfortunately, the present ESC guideline - like many other guidelines of the professional society - hardly goes beyond the mere declaration of the numerous conflicts of interest. There are no discernible approaches to reducing them, nor is there a conflict of interest management as is usual with AWMF guidelines (with e.g. abstentions, exclusion from management positions). After extensive internal discussions, we decided on 2 points for criterion 1 due to the many inconsistencies. All other reviews are explained in detail above.

Note: This evaluation was conducted with due care on the basis of the published guideline. Should you still discover an error, please contact us at info@leitlinienwatch.de.